Astrazeneca to share its robust early science in oncology with the medical community at AACR 2017
AstraZeneca | March 28, 2017
AstraZeneca, along with its global biologics research and development arm, MedImmune, will present the strength and depth of its translational science, which is expected to deliver the Company's next wave of innovative oncology medicines, at the American Association for Cancer Research (AACR) Annual Meeting in Washington DC, US, 1-5 April 2017.